Anna Padula
About Anna Padula
Anna Padula serves as the Senior Director of Global Pipeline and Product Communications at Kite Pharma, where she collaborates with cross-functional teams to enhance communications. With a background in communications and leadership from various prestigious programs, she has previously held significant roles at AstraZeneca and is motivated by the impact of her work on patient lives.
Current Role at Kite Pharma
Anna Padula serves as the Senior Director of Global Pipeline and Product Communications at Kite Pharma. She has held this position since 2022 and is based in Santa Monica, California. In her role, she collaborates with cross-functional and regional partners to align and optimize communications across the organization. Her work focuses on enhancing the visibility and understanding of Kite Pharma's product pipeline and therapeutic offerings.
Previous Experience at AstraZeneca
Prior to her current role, Anna Padula worked at AstraZeneca in various capacities. She served as Senior Manager of Regional Alliances from 2004 to 2008, followed by a position as Senior Manager of Alliance Development & Stakeholder Relations from 2008 to 2010. She then took on the role of Senior Manager of Brand Corporate Affairs from 2010 to 2012. Her experience at AstraZeneca provided her with a strong foundation in corporate communications and stakeholder engagement.
Education and Professional Development
Anna Padula has pursued extensive education and professional development in communications and leadership. She studied at St. Joseph's University, where she earned a Bachelor of Arts in English. Additionally, she completed several programs at GSK, including the Global Communications First Line Leaders Program, the Leadership Development Program, and Development Coach training. She is currently studying Communication and Media Studies at Page Society, achieving Page Society Page Up since 2022.
Motivation and Impact
Anna Padula is motivated by the opportunity to positively impact the lives of patients and their families through effective communications. Her commitment to authentic communication is evident in her work, where she aims to convey complex scientific information in a clear and relatable manner. This focus on patient-centric communication aligns with her deep understanding of CAR T-cell therapy and its market dynamics.